271 related articles for article (PubMed ID: 11328773)
1. In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model.
Robaux MA; Dube L; Caillon J; Bugnon D; Kergueris MF; Navas D; Le Conte P; Baron D; Potel G
J Antimicrob Chemother; 2001 May; 47(5):617-22. PubMed ID: 11328773
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.
Cappelletty DM; Kang SL; Palmer SM; Rybak MJ
Antimicrob Agents Chemother; 1995 Aug; 39(8):1797-801. PubMed ID: 7486921
[TBL] [Abstract][Full Text] [Related]
3. Amikacin + ceftazidime therapy of experimental right-sided Pseudomonas aeruginosa endocarditis in rabbits.
Bayer AS; Lam K; Norman D; Kim KS; Morrison JO
Chemotherapy; 1985; 31(5):351-61. PubMed ID: 3931992
[TBL] [Abstract][Full Text] [Related]
4. Development of beta-lactam resistance and increased quinolone MICs during therapy of experimental Pseudomonas aeruginosa endocarditis.
Bayer AS; Hirano L; Yih J
Antimicrob Agents Chemother; 1988 Feb; 32(2):231-5. PubMed ID: 3129985
[TBL] [Abstract][Full Text] [Related]
5. n-6 polyunsaturated fatty acids enhance the activities of ceftazidime and amikacin in experimental sepsis caused by multidrug-resistant Pseudomonas aeruginosa.
Giamarellos-Bourboulis EJ; Mouktaroudi M; Adamis T; Koussoulas V; Baziaka F; Perrea D; Karayannacos PE; Giamarellou H
Antimicrob Agents Chemother; 2004 Dec; 48(12):4713-7. PubMed ID: 15561848
[TBL] [Abstract][Full Text] [Related]
6. Killing of Pseudomonas aeruginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model.
Mouton JW; den Hollander JG
Antimicrob Agents Chemother; 1994 May; 38(5):931-6. PubMed ID: 8067772
[TBL] [Abstract][Full Text] [Related]
7. Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model.
Alou L; Aguilar L; Sevillano D; Giménez MJ; Echeverría O; Gómez-Lus ML; Prieto J
J Antimicrob Chemother; 2005 Feb; 55(2):209-13. PubMed ID: 15650000
[TBL] [Abstract][Full Text] [Related]
8. Conditions for the emergence of resistance to cefpirome and ceftazidime in experimental endocarditis due to Pseudomonas aeruginosa.
Fantin B; Farinotti R; Thabaut A; Carbon C
J Antimicrob Chemother; 1994 Mar; 33(3):563-9. PubMed ID: 8040120
[TBL] [Abstract][Full Text] [Related]
9. Adaptive resistance of Pseudomonas aeruginosa induced by aminoglycosides and killing kinetics in a rabbit endocarditis model.
Xiong YQ; Caillon J; Kergueris MF; Drugeon H; Baron D; Potel G; Bayer AS
Antimicrob Agents Chemother; 1997 Apr; 41(4):823-6. PubMed ID: 9087497
[TBL] [Abstract][Full Text] [Related]
10. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.
Benko AS; Cappelletty DM; Kruse JA; Rybak MJ
Antimicrob Agents Chemother; 1996 Mar; 40(3):691-5. PubMed ID: 8851594
[TBL] [Abstract][Full Text] [Related]
11. In vivo efficacy of humanised intermittent versus continuous ceftazidime in combination with tobramycin in an experimental model of pseudomonal pneumonia.
Croisier D; Martha B; Piroth L; Chavanet P
Int J Antimicrob Agents; 2008 Dec; 32(6):494-8. PubMed ID: 18804348
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of ceftazidime and aztreonam alone or in combination with amikacin in experimental left-sided Pseudomonas aeruginosa endocarditis.
Pefanis A; Giamarellou H; Karayiannakos P; Donta I
Antimicrob Agents Chemother; 1993 Feb; 37(2):308-13. PubMed ID: 8452362
[TBL] [Abstract][Full Text] [Related]
13. Pseudomonas peritonitis in neutropenic rats treated with amikacin, ceftazidime and ticarcillin, alone and in combination.
Shyu WC; Nightingale CH; Quintiliani R
J Antimicrob Chemother; 1987 Jun; 19(6):807-14. PubMed ID: 3112102
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of amikacin and ceftazidime in experimental aortic valve endocarditis due to Pseudomonas aeruginosa.
Bayer AS; Norman D; Kim KS
Antimicrob Agents Chemother; 1985 Dec; 28(6):781-5. PubMed ID: 3909954
[TBL] [Abstract][Full Text] [Related]
15. Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa.
Lu Q; Yang J; Liu Z; Gutierrez C; Aymard G; Rouby JJ;
Am J Respir Crit Care Med; 2011 Jul; 184(1):106-15. PubMed ID: 21474643
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamics of once-daily amikacin in various combinations with cefepime, aztreonam, and ceftazidime against Pseudomonas aeruginosa in an in vitro infection model.
McGrath BJ; Bailey EM; Lamp KC; Rybak MJ
Antimicrob Agents Chemother; 1992 Dec; 36(12):2741-6. PubMed ID: 1482142
[TBL] [Abstract][Full Text] [Related]
17. Once versus thrice daily tobramycin alone and in combination with ceftazidime, ciprofloxacin and imipenem in an in vitro pharmacodynamic model.
Zelenitsky SA; Karlowsky JA; Hoban DJ; Kabani A; Zhanel GG
Chemotherapy; 1998; 44(1):1-6. PubMed ID: 9444401
[TBL] [Abstract][Full Text] [Related]
18. Cefepime and amikacin synergy in vitro and in vivo against a ceftazidime-resistant strain of Enterobacter cloacae.
Mimoz O; Jacolot A; Padoin C; Tod M; Samii K; Petitjean O
J Antimicrob Chemother; 1998 Mar; 41(3):367-72. PubMed ID: 9578163
[TBL] [Abstract][Full Text] [Related]
19. Comparison of in vivo intrinsic activity of cefepime and imipenem in a Pseudomonas aeruginosa rabbit endocarditis model: effect of combination with tobramycin simulating human serum pharmacokinetics.
Navas D; Caillon J; Gras-Le Guen C; Jacqueline C; Kergueris MF; Bugnon D; Potel G
J Antimicrob Chemother; 2004 Oct; 54(4):767-71. PubMed ID: 15317741
[TBL] [Abstract][Full Text] [Related]
20. Lung deposition of continuous and intermittent intravenous ceftazidime in experimental Pseudomonas aeruginosa bronchopneumonia.
Girardi C; Tonnellier M; Goldstein I; Sartorius A; Wallet F; Rouby JJ;
Intensive Care Med; 2006 Dec; 32(12):2042-8. PubMed ID: 16858611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
